Publications
A record of the papers, preprints, posters and abstracts Baxtra has cleared for public release. It includes findings that narrowed a programme, exposed a transfer problem or stopped a line of work.
Current 31 August 2026. Publication status is not a statement that an investigational medicine is safe or effective. Author lines use roles and initials, not personal names.
A paper can be useful without being favourable. Several records describe a stopped compound, a failed assay transfer or a result that did not reproduce. A clear negative can be another laboratory’s lesson.
Peer-reviewed papers
Journal articles that have completed external peer review. The findings are presented in plain language; the linked record, where available, is the citable version.
| Title and authors | Venue and date | Finding |
|---|---|---|
| Structure-guided inhibition of Nipah F-glycoprotein conformational change Authors: Baxtra Research Labs, Structural Biology; A.M., R.S. and colleagues | Journal of Virology 12 February 2026 | The study mapped a small-molecule pocket on the fusion glycoprotein and identified a reproducible biochemical interaction for BX-101 Nipavir. Cell-based read-outs varied with assay format, so the paper treats the result as a starting point for optimisation rather than a treatment claim. |
| Intracellular activation and exposure limits of a Marburg L-polymerase nucleoside series Authors: Baxtra Research Labs, Discovery Chemistry; J.T., E.K. and colleagues | Antiviral Research 4 March 2026 | The series reached its intended intracellular triphosphate target in hepatocyte models, but several analogues also impaired mitochondrial respiration. The paper records the chemistry as abandoned for that reason; higher potency did not justify the cellular liability. |
| Lineage-dependent neutralisation by a Nipah fusion-site monoclonal antibody Authors: Baxtra Research Labs, Translational Virology; M.L., P.N. and colleagues | PLOS Neglected Tropical Diseases 28 March 2026 | The monoclonal retained binding to the reference panel but lost neutralisation against a Bangladesh-lineage isolate. That negative result removed a proposed single-antibody path and led the team to keep the finding visible rather than describe the antibody only by its stronger assays. |
| Cerebrospinal-fluid distribution of an antisense oligonucleotide in minipigs Authors: Baxtra Research Labs, Nucleic Acids; C.D., V.H. and colleagues | Molecular Therapy – Nucleic Acids 19 April 2026 | After intrathecal dosing, the prion oligonucleotide reached the lumbar and cervical sampling points but did not distribute beyond the cervical cord in this species. The work did not support the planned broad central nervous system exposure assumption for BX-308 Prionex. |
| Why an efflux-pump inhibitor potentiation signal did not reproduce across isolate collections Authors: Baxtra Research Labs, Antibacterial Pharmacology; L.Q., N.B. and colleagues | Antimicrobial Agents and Chemotherapy 7 May 2026 | An early collection suggested that the Meliovex beta-lactam combination could lower the required concentration of antibiotic. The potentiation did not reproduce in a second, geographically distinct bacterial isolate collection, and the manuscript reports the null result instead of treating the first collection as decisive. |
| Assay-transfer failure for a high-containment neutralisation endpoint Authors: Baxtra Research Labs, Bioassay Development; A.R., S.K. and colleagues | Journal of Virological Methods 2 June 2026 | Two contract laboratories received the same protocol, controls and reference material but produced materially different endpoint distributions. The transfer exercise failed its prespecified comparability rule. The paper identifies plate timing, cell passage and operator sequence as plausible contributors, not as proven causes. |
| Brain exposure was the limiting property in a rabies polymerase inhibitor series Authors: Baxtra Research Labs, Medicinal Chemistry; G.F., H.W. and colleagues | ACS Infectious Diseases 16 June 2026 | Several compounds had better enzyme and cell potency than the starting molecule, but measured exposure in the central nervous system remained below the internal target in the tested species. The series was dropped because potency without brain penetration was not a useful development profile. |
| Conformational coverage of a two-antibody Crimean-Congo haemorrhagic fever cocktail Authors: Baxtra Research Labs, Antibody Engineering; P.B., N.T. and colleagues | mAbs 9 July 2026 | Complementary binding sites on the CCHF glycoprotein complex were resolved and remained distinct in the tested conformations. The data support continued characterisation of BX-412 Cehafex, while leaving unanswered whether the combination will translate beyond controlled laboratory systems. |
| Negative-control behaviour in a pseudotyped arenavirus entry panel Authors: Baxtra Research Labs, Viral Entry Group; J.C., S.M. and colleagues | Virology 21 July 2026 | The proposed pan-arenavirus inhibitor showed no meaningful separation from its matched negative control in two entry formats. The paper concludes that the original screening signal was assay-dependent and should not be used to select a lead for BX-1265 Arenavir. |
| Repeatability of real-time perfusion imaging during simulated bowel anastomosis Authors: Baxtra Research Labs, Surgical Engineering; D.P., I.Y. and colleagues | Surgical Endoscopy 3 August 2026 | Across repeated simulated procedures, Lumavue produced a consistent perfusion map under the study conditions. The paper measures image repeatability and operator interpretation time; it does not establish improved patient outcomes or replace clinical judgement. |
Preprints
Manuscripts posted before or during journal review. A preprint may not have external peer review, and methods or conclusions may change.
| Title and authors | Repository and date | Finding |
|---|---|---|
| Endothelial barrier markers after S1PR1 agonism in an Andes-virus model Authors: Baxtra Research Labs, Host Response Biology; R.B., A.L. and colleagues | bioRxiv 14 January 2026 | Hantrelvir changed a panel of endothelial barrier markers in the model and the direction was consistent across two runs. The preprint describes a pharmacology signal only; it does not show that vascular leakage, hospitalisation or another clinical outcome would change. |
| Variant mapping for a Sudan ebolavirus glycan-cap antibody pair Authors: Baxtra Research Labs, Antibody Discovery; E.M., T.R. and colleagues | Research Square 11 February 2026 | Mapping identified substitutions that reduced binding by one antibody while leaving the companion antibody’s epitope available in the tested panel. The result informs surveillance and combination design, but the panel is not a forecast of field performance. |
| Resistance selection and recovery of p37 inhibition in orthopoxvirus culture Authors: Baxtra Research Labs, Antiviral Resistance; N.H., S.V. and colleagues | medRxiv 8 March 2026 | Selection experiments produced p37 substitutions with reduced susceptibility to Poxavir, while several substitutions also reduced viral fitness in the culture system. The preprint reports both observations and does not infer that the same balance would occur in an infected person. |
| Pharmacokinetic bridging of a fixed arenavirus fusion-inhibitor formulation Authors: Baxtra Research Labs, Clinical Pharmacology; C.F., M.J. and colleagues | SSRN 17 April 2026 | Oral and intravenous exposures could be related with a model within the prespecified uncertainty range in healthy volunteers. The analysis supports dose selection for further study but does not supply an efficacy result or establish a clinically useful exposure. |
| Fc-silent redesign of a Lassa glycoprotein B-site antibody Authors: Baxtra Research Labs, Protein Sciences; P.R., L.D. and colleagues | bioRxiv 22 May 2026 | The Fc-silent redesign reduced binding to the intended cellular Fc receptor panel but also reduced the neutralisation signal in the study’s cell assay. Because the change did not preserve the desired profile, that antibody format was not advanced for BX-515 Lassivar. |
| SealWeave staple-line sealant under cyclic pressure: a null comparison Authors: Baxtra Research Labs, Surgical Materials; K.O., M.P. and colleagues | Research Square 5 August 2026 | In the bench model, SealWeave did not differ from the comparator on burst pressure at the prespecified time points. The result is a null mechanical comparison, not evidence that the device is ineffective in surgery, and further clinical evaluation remains investigational. |
Conference posters and abstracts
Short-form records are included when they disclose a defined method and result. An abstract is not a substitute for a complete study report.
| Title and authors | Meeting and date | Finding |
|---|---|---|
| Early tolerability observations from SENTINEL-1 dose escalation Authors: Baxtra Research Labs, Clinical Operations; S.A., V.N. and colleagues | American Society for Virology annual meeting Poster, 18 June 2026 | The poster summarises protocol-defined safety observations and exposure ranges from the first cohorts of the BX-101 study. It is an early clinical description, not a test of whether Nipavir prevents or treats Nipah virus infection. |
| CSF target-engagement assay repeatability for VIGIL-0 Authors: Baxtra Research Labs, Translational Biomarkers; Y.K., Q.R. and colleagues | Prion Disease Research Conference Abstract, 26 June 2026 | A blinded repeat-read exercise showed acceptable agreement for the cerebrospinal-fluid assay when the same reference controls were used. The result supports measurement reliability only; it does not show that a change in the marker alters disease progression. |
| Fixed-pair exposure margins for Riftavir in a non-human primate model Authors: Baxtra Research Labs, Translational Pharmacology; H.B., N.J. and colleagues | International Congress of Virology Poster, 9 July 2026 | The fixed Gn-antibody and polymerase-inhibitor pair reached the planned plasma exposure range in the model without a dose-limiting observation in this experiment. The poster does not establish a protective dose in humans or a clinical benefit. |
| Second-isolate review of beta-lactam potentiation by BX-1620 Authors: Baxtra Research Labs, Microbiology; W.F., T.C. and colleagues | European Congress of Clinical Microbiology Abstract, 19 July 2026 | The expanded isolate review did not reproduce the potentiation reported in the discovery collection. The abstract was accepted because the discrepancy changes how the combination should be evaluated, not because it presents a favourable activity result. |
| Task completion with Axion OR in a simulated soft-tissue workflow Authors: Baxtra Research Labs, Human Factors; P.E., R.M. and colleagues | Society of Robotic Surgery meeting Poster, 2 August 2026 | Users completed the simulated workflow, but the study found no meaningful reduction in task errors compared with the manual instrument condition. The null result prompted a change to the training protocol; Axion OR remains an investigational platform. |
| Bangladesh-lineage escape from a candidate Nipah monoclonal Authors: Baxtra Research Labs, Global Virus Surveillance; U.D., G.S. and colleagues | Asia-Pacific Emerging Infections Forum Abstract, 15 August 2026 | The abstract reports loss of neutralisation for the candidate monoclonal against one Bangladesh-lineage isolate while the broader reference panel remained positive. It was presented to make the boundary of the data visible and to prevent a broad neutralisation statement from being repeated without qualification. |
Why publish results that did not work
Negative work is not a consolation prize. It tells another laboratory not to repeat a failed transfer, shows a medicinal chemist which liability mattered more than potency, and shows readers what the data cannot carry. Hiding a boundary is more dangerous than admitting one.
We publish null results because a favourable first experiment is not necessarily dependable. The Meliovex potentiation signal appeared in one isolate collection and did not reproduce in the second; publishing only the first would mislead.
For reproducibility
Methods, controls and the decision rule are described so an independent group can see what was tested and where the result stopped being reliable.
For programme decisions
A dropped series is evidence about a property that was not acceptable at the time. It is not a claim that every related molecule, formulation or indication has been ruled out.
For the public record
A company that only publishes its successes is not publishing, it is advertising. We would rather leave a shorter, less flattering record that can be read without promotional interpretation.
A null publication can still be incomplete. We state the model, isolate collection, species, assay and decision boundary where cleared. We do not turn an absence of evidence into an absence of biology.
What Baxtra commits to putting on the record
Publication decisions are reviewed by the scientific lead, study owner and Disclosure Review Board for safety, privacy, security and partner confidentiality. This is not a second opportunity to remove an inconvenient result. Operational details may be omitted for biosafety or security, but the direction of a finding must not change.
We commit to publish
Completed studies with a defined question and interpretable methods, including negative, null, inconclusive and stopped studies. We publish relevant protocol deviations, corrections, and changes between poster, preprint and final paper.
We do not publish
Patient-identifiable information, unredacted participant-level records, partner material without permission, or operational details that increase high-consequence pathogen risk. We do not make unsupported claims or disguise withheld material as a result.
When we publish
Our target is submission or posting within twelve months after completion, measured from the last participant’s final visit or last prespecified analysis, whichever is later. If review or redaction delays release, we record the reason and release the cleared summary as soon as possible.
When the study stops early
Early stop is not an exemption. We aim to publish the reason and material findings within twelve months, subject to privacy and security limits. “No result” is not a substitute for explaining what was learned.
This policy covers Baxtra-sponsored work and studies where Baxtra is responsible sponsor. A partner contract may control the route and timing of a final manuscript, but not erase a material negative finding. Requests about a listed item go to disclosure@baxtra.pages.dev.
Publication is one part of the record
The science overview explains the portfolio. The document library holds cleared fact sheets, study transparency material and governance documents. None turns an investigational candidate into an approved medicine.